Please assess the completion status of the following clinical trial:

Trial Title: Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed diagnosis of melanoma~* Previously treated or previously untreated stage IV melanoma by American Joint Committee on Cancer (AJCC) staging criteria~* Presence of an index lesion between 1 and 5 cm~* Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2~* Signed informed consent document~* Adequate renal, hepatic, and hematologic indices for ipilimumab therapy~* Ability to tolerate stereotactic body radiation therapy (e.g. lie flat and hold position for treatment)~Exclusion Criteria:~* Prior systemic therapy within 14 days of study enrollment; patients must be adequately recovered from prior systemic therapy side effects as deemed by the treating investigator~* Clinical contraindication to stereotactic body radiotherapy (e.g. active systemic sclerosis, active inflammatory bowel disease if bowel is within target field, etc)~* Presence of central nervous system metastasis (including active brain metastasis); active brain metastasis would be defined as untreated brain metastases; if the brain metastases have received prior treatment (usually either with surgery or radiation), they are no longer active~* Long-term use of systemic corticosteroids; patients with replacement steroids and not immunosuppressive steroids may enroll in the study~* Prior radiation therapy (RT) that precludes the delivery of SBRT

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (stereotactic body radiotherapy, ipilimumab) (Type: EXPERIMENTAL): Patients undergo a total of 3 fractions of stereotactic body radiotherapy between days 1-13. Patients then receive ipilimumab IV every 3 weeks. Treatment repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).